GR3035996T3 - PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE - Google Patents
PYRROLO[2,3-d]PYRIMIDINES AND THEIR USEInfo
- Publication number
- GR3035996T3 GR3035996T3 GR20010400849T GR20010400849T GR3035996T3 GR 3035996 T3 GR3035996 T3 GR 3035996T3 GR 20010400849 T GR20010400849 T GR 20010400849T GR 20010400849 T GR20010400849 T GR 20010400849T GR 3035996 T3 GR3035996 T3 GR 3035996T3
- Authority
- GR
- Greece
- Prior art keywords
- compounds
- alkyl
- pct
- trifluoromethyl
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH295394 | 1994-09-29 | ||
PCT/EP1995/003536 WO1996010028A1 (en) | 1994-09-29 | 1995-09-08 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3035996T3 true GR3035996T3 (en) | 2001-09-28 |
Family
ID=4245363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20010400849T GR3035996T3 (en) | 1994-09-29 | 2001-06-06 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE |
Country Status (20)
Country | Link |
---|---|
US (1) | US5869485A (el) |
EP (1) | EP0783505B1 (el) |
JP (1) | JP4145955B2 (el) |
KR (1) | KR970706288A (el) |
CN (1) | CN1046731C (el) |
AT (1) | ATE199553T1 (el) |
AU (1) | AU694801B2 (el) |
BR (1) | BR9509048A (el) |
CA (1) | CA2200210A1 (el) |
DE (1) | DE69520282T2 (el) |
DK (1) | DK0783505T3 (el) |
ES (1) | ES2157344T3 (el) |
FI (1) | FI112867B (el) |
GR (1) | GR3035996T3 (el) |
HU (1) | HU222181B1 (el) |
MX (1) | MX9702307A (el) |
NO (1) | NO308108B1 (el) |
NZ (1) | NZ293249A (el) |
PT (1) | PT783505E (el) |
WO (1) | WO1996010028A1 (el) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE159257T1 (de) * | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
DE69619114T2 (de) * | 1995-07-06 | 2002-10-02 | Novartis Ag | Pyrolopyrimidine und verfahren zu ihrer herstellung |
AU3176297A (en) * | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
JP4056589B2 (ja) * | 1996-07-19 | 2008-03-05 | 武田薬品工業株式会社 | 複素環化合物、その製造法および用途 |
WO1998003505A2 (en) * | 1996-07-19 | 1998-01-29 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
AU720429B2 (en) | 1996-08-23 | 2000-06-01 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
JP4205168B2 (ja) | 1996-10-02 | 2009-01-07 | ノバルティス アクチエンゲゼルシヤフト | ピリミジン誘導体およびその製造法 |
GB9704948D0 (en) | 1997-03-11 | 1997-04-30 | Knoll Ag | Therapeutic agents |
WO1998041525A1 (en) * | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
HUP0002956A3 (en) * | 1997-08-05 | 2002-01-28 | Pfizer Prod Inc | Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y |
JP4611524B2 (ja) * | 1998-06-02 | 2011-01-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ピロロ[2,3d]ピリミジン組成物およびその使用 |
ID29028A (id) * | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
CN1390219A (zh) | 1999-09-17 | 2003-01-08 | 艾博特股份有限两合公司 | 作为治疗剂的吡唑并嘧啶类 |
US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
CA2450777C (en) | 2001-08-10 | 2013-04-09 | Novartis Ag | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
ES2436877T3 (es) | 2005-11-17 | 2014-01-07 | OSI Pharmaceuticals, LLC | Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados |
JP5512975B2 (ja) * | 2005-12-29 | 2014-06-04 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬 |
TW200738725A (en) * | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
WO2009117482A1 (en) * | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms |
JP5819195B2 (ja) * | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
WO2010066629A2 (en) * | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
CN102712648A (zh) | 2009-11-25 | 2012-10-03 | 诺瓦提斯公司 | 双环杂芳基的与苯稠合的6元含氧杂环衍生物 |
EP2582680A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
JP2013532149A (ja) | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体 |
EP2683722A1 (en) | 2011-03-08 | 2014-01-15 | Novartis AG | Fluorophenyl bicyclic heteroaryl compounds |
ES2740399T3 (es) | 2011-03-09 | 2020-02-05 | Richard G Pestell | Líneas de células de cáncer de próstata, firmas genéticas y usos de estas |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
CA2873743C (en) | 2012-05-14 | 2022-12-06 | Prostagene, Llc | Using modulators of ccr5 for treating cancer |
BR112015006828A8 (pt) | 2012-09-26 | 2019-09-17 | Univ California | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 |
WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
EP3194572B1 (en) | 2014-07-30 | 2023-10-25 | Yeda Research and Development Co. Ltd. | Media for culturing pluripotent stem cells |
WO2017027883A1 (en) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
EP3914698A1 (en) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
ATE159257T1 (de) * | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
-
1995
- 1995-09-08 PT PT95932693T patent/PT783505E/pt unknown
- 1995-09-08 WO PCT/EP1995/003536 patent/WO1996010028A1/en active IP Right Grant
- 1995-09-08 AT AT95932693T patent/ATE199553T1/de not_active IP Right Cessation
- 1995-09-08 DE DE69520282T patent/DE69520282T2/de not_active Expired - Lifetime
- 1995-09-08 CA CA002200210A patent/CA2200210A1/en not_active Abandoned
- 1995-09-08 EP EP95932693A patent/EP0783505B1/en not_active Expired - Lifetime
- 1995-09-08 HU HU9701333A patent/HU222181B1/hu not_active IP Right Cessation
- 1995-09-08 NZ NZ293249A patent/NZ293249A/en active IP Right Revival
- 1995-09-08 MX MX9702307A patent/MX9702307A/es not_active IP Right Cessation
- 1995-09-08 AU AU35643/95A patent/AU694801B2/en not_active Ceased
- 1995-09-08 JP JP51131296A patent/JP4145955B2/ja not_active Expired - Fee Related
- 1995-09-08 KR KR1019970702044A patent/KR970706288A/ko active IP Right Grant
- 1995-09-08 BR BR9509048A patent/BR9509048A/pt not_active IP Right Cessation
- 1995-09-08 ES ES95932693T patent/ES2157344T3/es not_active Expired - Lifetime
- 1995-09-08 DK DK95932693T patent/DK0783505T3/da active
- 1995-09-08 CN CN95196308A patent/CN1046731C/zh not_active Expired - Fee Related
- 1995-09-08 US US08/793,313 patent/US5869485A/en not_active Expired - Lifetime
-
1997
- 1997-03-21 NO NO971342A patent/NO308108B1/no not_active IP Right Cessation
- 1997-03-24 FI FI971225A patent/FI112867B/fi active
-
2001
- 2001-06-06 GR GR20010400849T patent/GR3035996T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT783505E (pt) | 2001-08-30 |
DE69520282D1 (de) | 2001-04-12 |
BR9509048A (pt) | 1998-01-06 |
EP0783505B1 (en) | 2001-03-07 |
NO971342L (no) | 1997-03-21 |
HUT76785A (en) | 1997-11-28 |
NO308108B1 (no) | 2000-07-24 |
KR970706288A (ko) | 1997-11-03 |
ES2157344T3 (es) | 2001-08-16 |
FI112867B (fi) | 2004-01-30 |
ATE199553T1 (de) | 2001-03-15 |
FI971225A0 (fi) | 1997-03-24 |
FI971225A (fi) | 1997-05-14 |
US5869485A (en) | 1999-02-09 |
JP4145955B2 (ja) | 2008-09-03 |
JPH10506624A (ja) | 1998-06-30 |
HU222181B1 (hu) | 2003-04-28 |
CA2200210A1 (en) | 1996-04-04 |
AU694801B2 (en) | 1998-07-30 |
CN1164234A (zh) | 1997-11-05 |
CN1046731C (zh) | 1999-11-24 |
NZ293249A (en) | 1999-04-29 |
NO971342D0 (no) | 1997-03-21 |
EP0783505A1 (en) | 1997-07-16 |
WO1996010028A1 (en) | 1996-04-04 |
DE69520282T2 (de) | 2001-08-09 |
DK0783505T3 (da) | 2001-07-02 |
AU3564395A (en) | 1996-04-19 |
MX9702307A (es) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3035996T3 (en) | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | |
DK0938486T3 (da) | Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling | |
EA200200473A1 (ru) | Ингибиторы тирозинкиназы | |
AP2002002643A0 (en) | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors | |
NO975956D0 (no) | Pyrrolopyrimidiner og fremgangsmåter for deres fremstilling | |
MY134848A (en) | Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases | |
DE69216158T2 (de) | Chinazolinderivate enthaltende therapeutische Zusammensetzungen | |
MY128370A (en) | Pyrrolotriazane inhibitors of kinases | |
BG104996A (en) | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation | |
CY1105618T1 (el) | Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης | |
BG103785A (en) | Pyrrolo[2,3-d]pyrimidines and their application as tyrosine kinase inhibitors | |
DE69713273D1 (de) | Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms | |
EP1233950A4 (en) | 3,4-DIHYDRO (1H) CHINAZOLIN 2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS | |
DK0526588T3 (da) | Heterocykliske forbindelser, deres fremstilling og anvendelse | |
ATE150751T1 (de) | Neuroprotektive 3,4-dihydro-2(1h)-chinolone | |
MXPA05010975A (es) | Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide. | |
DOP2001000226A (es) | Proceso para preparar 2-(4-piridil) amino-6-dialqui- loxifenil-pirido [2,3-d] pirimidin-7-onas (process for preparing 2-(4-pyridil) amino-6-dialkyphenyl-pyrido 2,3-d] | |
ATE193705T1 (de) | 4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen- - on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie | |
RU95106462A (ru) | Производные пирролопиримидина, имеющие фармакологическую активность | |
ATE408606T1 (de) | Neue 3-substituierte 1,2,4-benzotriazine, verfahren zu ihrer herstellung und ihre verwendung zur behandlung und prophylaxe von tumorerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ML | Lapse due to non-payment of fees |
Effective date: 20110404 |